Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00450879 · ClinicalTrials.gov registry record · Phase 1
Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT00450879: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00450879 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00450879, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This pilot clinical trial studies how well pazopanib hydrochloride works in treating patients with breast cancer that is newly diagnosed or has come back at or near the same place as the original tumor and can be removed by surgery. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by preventing the growth of new blood vessels necessary for tumor growth. Giving pazopanib hydrochloride before surgery may make the tumor smaller and reduce the amount of tissue that needs to be removed.
Interventions
- OTHER Laboratory Biomarker Analysis
- PROCEDURE Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- OTHER Pharmacological Study
- DRUG Pazopanib Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2007-01 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00450879
The ClinicalTrials.gov registry entry for NCT00450879 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00450879 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00450879 about?
NCT00450879 is a clinical study titled "Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery". This pilot clinical trial studies how well pazopanib hydrochloride works in treating patients with breast cancer that is newly diagnosed or has come back at or near the same place as the original tumor and can be removed by surgery. Pazopanib hydrochloride may stop the growth of tumor cells by block...
What is the current status of trial NCT00450879?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2007-01. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00450879?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Dynamic Contrast-Enhanced Magnetic Resonance Imaging (PROCEDURE), Pharmacological Study (OTHER), Pazopanib Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00450879?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.